[BUY] a2 Milk (ASX: A2M) – Paying Now to Rebuild China Label for an FY28 Rebound
Buy: institutional sell-side target A$8.20 for a2 Milk (ASX: A2M) A$7.31 ▼ -1.08%, 11.0 per cent above the share price of A$7.39, as it rebuilds China label sales.

Buy: institutional sell-side target A$8.20 for a2 Milk (ASX: A2M) A$7.31 ▼ -1.08%, 11.0 per cent above the share price of A$7.39, as it rebuilds China label sales.
Buy: institutional sell-side target A$18.20 for Lynas Rare Earths is 38.0 per cent above the share price, with floor prices now on over half its output.
Buy: institutional sell-side target A$182.50 for CSL sits 10.1 per cent below the A$202.92 close, as FY27 guidance holds after the AGM.
Buy, A$12.60 target, 9.6 per cent above A$11.50. Institutional sell-side research expects aerospace and defence to drive most of PWR Holdings’ growth.
Buy (institutional sell-side), A$11.20 target, 4.0 per cent above the share price of A$10.77. BEN yields 5.8 per cent, fully franked.

A close New Zealand election puts the coalition deal, and Labour’s 28 per cent capital gains tax on investment property, at the centre for investors.
RBA statements carry only a faint signal on rate moves, and just 29 per cent of Australians know its employment mandate, new research finds.
The RBA has dropped forward guidance and its hedging language has risen since 2023, coinciding with bigger market surprises on decision days.

Buy rated by institutional sell-side research, US$700.00 target, 35.9 per cent upside, as AMD’s Datacenter strength lifts fourth quarter guidance.
Buy, US$215.00 target, 14.8 per cent upside. CoreSite data center growth and a US$2.0 billion buyback offset a soft US leasing quarter for AMT.
Buy rated by institutional sell-side research with a US$915.00 target, 37.5 per cent upside, after Teledyne beat and raised 2026 guidance.
Buy, US$670.00 target, 65.4 per cent upside, per institutional sell-side research. AI equipment demand and higher margin targets drive Applied Materials.
Buy rated by institutional sell-side research with a US$32.00 target, 148.6 per cent upside, ahead of Phase 3 wet AMD gene therapy data in 2Q27.
Defense spending is tilting toward drones, counter-drone systems and munitions on a $1.15 trillion base budget, says institutional sell-side research.
US tech outlook: AI is pushing software spend toward fewer platforms with hard-to-copy data. One example covers more than 240mn US consumers.
Healthcare outlook: new drug launches drive sector growth, with an HIV prevention injection keeping more than 70 per cent of users at six months.
Orezone Gold Corporation reported record quarterly gold production of 59,674 ounces in the third quarter of 2026, translating to revenue of USD 238.5 million and adjusted EBITDA of USD 111.8 million. The company generated operating cash flow of USD 71.1 million during...
Tony O'Malley's first four months as CEO of IPH Limited have delivered a sobering early warning: the intellectual property services group is grappling with material headwinds that extend beyond currency movements. While the company delivered a solid FY26 result with...
Technology One delivered its 17th consecutive year of record profit and revenue in FY26, with profit before tax reaching $217.6 million, up 20%, and annual recurring revenue climbing to $652.1 million, up 18% on a constant currency basis. The company hit the top of...
TechnologyOne delivered profit before tax of $217.6 million, up 20 percent for the year ended 30 September 2026, hitting the top end of upgraded guidance despite significant...
Technology One Limited delivered net profit of $163.4 million for the financial year ended 30 September 2026, representing 18.7% growth on the prior year's result of $137.6...
Finding the best shares to buy on the ASX requires more than just scanning a screener or chasing whatever is up this week. We focus on companies with strong competitive positioning, visible earnings growth, and a catalyst to drive the share price higher over the next...
Dividend investing on the ASX remains one of the most reliable ways to build long-term wealth. Blue chip dividend stocks offer a combination of regular income and capital growth that is difficult to replicate through other strategies, particularly in an environment...
US equities offer Australian investors access to some of the most innovative and fastest-growing companies in the world. The sheer depth of the American market means there are opportunities across sectors that simply do not exist on the ASX, from cutting-edge biotech...
Subscribe today for free and get an alert when we have new research and webinars.
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000